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Open issues with regard to the clinical use of erythropoietic growth fac-
tors include starting Hb threshold, characterization of responders or non-
responders, the role of iron supplementation and the impact of costs. 
In summary, anemia is of major clinical relevance in patients with lung 
cancer and its management according to published practice guidelines 
will beneﬁt many patients with lung cancer.
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Neurotoxicity
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The peripheral nervous system is frequently the site of the toxic action 
of several drugs. The target of drug-induced neurotoxicity is mostly 
dependent on the type of substance which can act predominantly on the 
nerve ﬁbers (axon or myelin) or on the neuronal body (motoneurons 
or dorsal root ganglia primary sensory neurons). Accordingly, also 
the clinical features of drug-induced neuropathy are dependent on the 
type of agent involved, ranging from predominantly motor, to almost 
exclusively sensory or sensory-motor neuropathies, with or without 
any clinical evidence of autonomic impairment. On clinical grounds, 
several classes of very effective drugs induce sensory and/or motor 
impairment during chemotherapy or even after treatment withdrawal, 
depending on the target and site of the neurotoxic action. 
The features of the neurotoxic drugs currently involved in the treatment 
of lung cancer or with a possible future indication will be reviewed. 
Among the platinum compounds with well-established clinical use, 
cisplatin is the most severely neurotoxic. Platinum drugs appear to 
affect primarily the sensory neurons in the dorsal root ganglia where no 
blood-brain barrier is present. Cisplatin-induced neuropathy is sensory, 
predominantly characterized by symptoms of large myelinated ﬁbre 
damage, such as numbness and tingling, paresthesias of the upper and 
lower extremities, reduced vibration and position sense perception, 
reduced deep tendon reﬂexes, and incoordination with gait disturbance. 
After completion of cisplatin chemotherapy only a part of the patients 
has signiﬁcant neurotoxic symptoms, whereas 3-4 months later the 
proportion is deﬁnitely higher (the “coasting” phenomenon). Conven-
tional dosages of carboplatin have been associated with a lower risk of 
peripheral neuropathy than cisplatin. Besides chronic sensory neurotox-
icity, in about 90% of patients oxaliplatin treatment has been associated 
with acute neurosensory toxicity, including dysesthesia and paresthesia.
Several putative neuroprotective agents (i.e. Org2766, reduced gluta-
thione, nerve growth factor, BNP7787, acetyl-L-carnitine, xaliproden, 
vitamin E, ...) are currently undergoing pre-clinical and/or clinical 
investigation.
The antitubulin drugs are among the most promising agents for the 
current and future treatment of cancer, since not only are they already 
part of well-established chemotherapy schedules, but also several new 
drugs are currently in the pre-clinical phase or are in phase-I/II clinical 
development. At present, two families of antitubulin agents, acting with 
opposite mechanisms of action, are widely used to treat cancer: the 
taxanes and the vinca alkaloids. Among the taxanes, paclitaxel is more 
neurotoxic than docetaxel but in both cases neurotoxicity may be dose-
limiting. The clinical features of the peripheral neurotoxicity induced 
by taxanes are qualitatively identical, and they are mostly represented 
by distal, symmetrical hypoesthesia in the upper and lower extremi-
ties with a length-dependent distribution. In most cases, all sensory 
modalities are affected and deep tendon reﬂex loss is an early feature of 
taxanes’ peripheral neurotoxicity. Motor signs and symptoms can occur 
during treatment with paclitaxel or docetaxel, although only rarely 
is motor impairment a clinically-relevant feature. Very rarely distal 
neuropathic pain may ensue during taxane treatment, while myalgia 
is a frequent symptom. The signs of taxanes’ peripheral neurotoxicity 
tend to be reversible but, in a minority of cases, persistence of sensory 
impairment is observed and incomplete recovery can occur.
Neuroprotective strategies have been tested using Org2766, glutamine, 
leukaemia inhibitor factor, acetyl-L-carnitine and BNP7787.
Most of the patients treated with vincristine develop dose-dependent 
potentially treatment-limiting neurotoxicity with the clinical features 
of a sensorimotor peripheral neuropathy caused by inhibition of 
anterograde and retrograde axonal transport secondary to microtubule 
damage. Sensory signs and symptoms are predominant in the major-
ity of the patients, with distal symmetrical hypoesthesia and dyses-
thesia involving all the sensory modalities (i.e. deep and superﬁcial), 
sometimes with a painful component. Muscular cramps can occur, in 
association with reduced strength in the distal muscles, in the most 
severely affected patients. Severe impairment of motor function leading 
to tetraplegia has occasionally been described in children or in patients 
with pre-existing hereditary neuropathies. Similarly, there have been 
occasional reports of isolated peripheral nerve functional impairment. 
Rarely, the “coasting” phenomenon has been described also with vin-
cristine. Autonomic nervous system involvement is observed in about 
one third of the subjects exposed to vincristine presenting with ortho-
static hypotension, urinary bladder dysfunction and erectile impotence. 
However, the most severe clinical occurrence is constipation due to a 
paralytic ileus or megacolon. The toxic signs induced by vincristine 
are reversible in most cases, but long-lasting impairment or incomplete 
recovery are frequent.
Neuroprotection with insulin-like growth factor-1 (IGF-1) has been 
achieved in one of the several animal models developed to investigate 
vincristine peripheral neurotoxicity, but no data in humans have so far 
been reported.
Among newly-developed antitubulin substances, epothilones have 
aroused considerable excitement, being extremely active as a microtu-
bule stabilizer, with an effect which is the same as that observed with 
taxanes. Given the common mechanism of action, it is not surprising 
that epothilones, similarly to taxanes, can induce dose-limiting periph-
eral neurotoxicity. However, the data available so far do not make it 
possible to have a clear picture of the clinical presentation of epothi-
lone-induced nerve impairment and no conclusive data are available on 
the time course of epothilone-induced neuropathy or on its site of ac-
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tion, but it likely that this side effect will signiﬁcantly affect the clinical 
use of this very promising class of antineoplastic drugs.
The ubiquitin-proteasome pathway is the major proteolytic system in 
the cytosol and nucleus of all eukariotic cells and a target for anticancer 
chemotherapy. Although it is in no way clear how and where bortezo-
mib (the ﬁrst-in-class proteasome inhibitor) administration can affect 
the peripheral nervous system, at least one-third of the patients under 
treatment have had evidence of clinically-relevant sensory peripheral 
neuropathy. Treatment withdrawal resulted in clinical improvement, 
but the low number of patients studied makes it impossible to draw any 
ﬁrm conclusion about this. 
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Treatment-related pneumonitis continues to be a problem in patients 
receiving thoracic radiotherapy (RT), occurring (≥Grade 3) in 13-16% 
of patients treated with the 3-dimensional RT alone or with concurrent 
chemotherapy. Treatment-related pneumonitis can result in death in 2-
3% of patients. Pneumonitis usually does not affect the delivery of RT, 
being a subacute or late toxicity, but may result in death or signiﬁcant 
disability.
The incidence of treatment-related pneumonitis reported in the RTOG 
experience of four clinical trials of concurrent chemoradiotherapy in 
patients with inoperable NSCLC (Werner-Wasik et al, 2002; Bradley et 
al, 2005) was as follows: Grade 1, 24%; Grade 2, 22%; Grade 3, 16%; 
Grade 4, 2% and Grade 5, 2%. Interestingly, a similar incidence of 
pneumonitis was observed in the RT dose -escalation study of radio-
therapy alone, without chemotherapy (13-16% Grade≥3; Bradley et 
al, 2005). In a recently reported experience from a Phase III SWOG 
(Southwest Oncology Group) 0023 study of concurrent chemoradio-
therapy, docetaxel consolidation and placebo vs. geﬁtinib consolidation 
in 620 NSCLC patients (Gaspar et al, 2005), severe (Grade≥3) pneu-
monitis was observed in 9% of all patients and in 16% of the patient 
subset whose RT records were reviewed in detail. 
Symptomatic pneumonitis classically develops between 1-6 months 
from completion of thoracic RT, although new cases of pneumonitis 
were observed in the RTOG database up to 18 months. It manifests as 
cough, dyspnea and rarely, fever. In patients with chronic lung disease, 
the symptoms of pneumonitis may be difﬁcult to distinguish form the 
underlying lung disease. Treatment-related pneumonitis remains there-
fore a diagnosis of exclusion.
The most current grading system for pneumonitis is that provided by 
the United States NCI (National Cancer Institute) Common Termi-
nology Criteria for Adverse Events v3.0 (CTCAE), where Grade 3 
pneumonitis is deﬁned as “Symptomatic, interfering with Activities 
of Daily Living; oxygen indicated”, and Grade 4 as “Life-threatening; 
ventilatory support indicated”. 
The treatment of established symptomatic treatment-related pneumo-
nitis remains supportive, consisting of prednisone, usually initiated at 
a daily dose of 40-60 mg followed by a very slow taper over several 
weeks. Antibiotics, bronchodilators, oxygen and ventilatory support are 
used as needed.
Several predictive factors are thought to be associated with pneumo-
nitis, including irradiated lung volume, RT dose, RT fraction size and 
frequency, pre-RT lung reserve and interaction with chemotherapy. 
Among the dosimetric tools, the “V
dose
”, or volume of the lung receiv-
ing a certain minimum RT dose (for example, “V
20
”, or volume of the 
lung receiving 20 Gy or more), is a simple and practical tool applicable 
to daily radiation planning. Values of V
20
<25% are rarely (<10%) as-
sociated with radiation pneumonitis (Graham M et al, 1999), although 
such a low V
20
 can be accomplished only for small lung tumors. Most 
cooperative groups (RTOG, SWOG) allow a V
20
 of <35% as a fairly 
safe and yet feasible value for most deﬁnitively treated lung cancers. 
Mean Lung Dose (MLD) is another dosimetric indicator of the risk of 
pneumonitis, which seems to correlate very closely with the V
20
 (Can-
dish et al, 2005). Of note, the validity of the V
20
 is preserved only for 
standard RT fractions. For larger fraction sizes V
20
 values may need to 
be lower (for example, V
20
 becomes V
18
 for a fraction size of 2.5 Gy). 
Hyperfractionated regimens, such as CHART (Continuous Hyperfrac-
tionated Radiation Therapy) may require yet a different V
dose
 as a pre-
dictor of RP. In patients after pneumonectomy, the value of V20 may 
need to be at least halved to predict safe delivery of postoperative RT. 
Despite those limitations, the V
20
 constraint remains a useful guideline 
for patients receiving standard -fractionated RT. Although dosimetric 
parameters are associated with RP risk, they do not have high predic-
tive power (PPV, or Positive Predictive Power of 18-38%; Rodrigues 
et al, 2004). Therefore, biologic models are needed to improve the 
accuracy of prediction.
There are no universally accepted serum markers predicting radiation 
pneumonitis, although TGF-beta (transforming growth factor-beta) has 
been suggested by some investigators to be valuable, particularly when 
combined with a dosimetric factor, such as the V
20
 (Fu 2001). 
So far no measures have been approved as providing effective pre-
vention of pneumonitis. Amifostine administered during concurrent 
chemoradiotherapy in locally advanced NSCLC was reported to lower 
the risk of high-grade pneumonitis in one institutional randomized trial 
(Komaki R et al, 2002), but this observation was not conﬁrmed in the 
large RTOG 98-01 Phase III randomized study (Movsas et al 2005). 
Other potential lung protectors (keratinocyte growth factors, superoxide 
dismutase) will need to be further tested in randomized trials in patients 
with lung cancer to prove their value. 
In summary, RP continues to challenge patients with lung cancer and 
the clinicians taking care of them. More basic and clinical research is 
necessary to accurately predict and treat this complication of therapy of 
thoracic malignancies.
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Pain is not universal in lung cancer, but is common, is present in about 
25% of patients at presentation with an increase to about 50% later. 
Most reviews report that it is often inadequately relieved when severe. 
Pain syndromes found in lung cancer and mesothelioma can be catego-
rised as follows:
1. Sub (retro) - sternal visceral pain 
2. Unilateral visceral pain
3. Chest wall pain (including brachial plexopathy)
4. Post-Thoracotomy 
5. Pain from metastases (especially bone, liver, brain)
